Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allo-transplant recipients.
Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes / Maffi, P., Lundgren, T., Tufveson, G., Rafael, E., Shaw, J.A.M., Liew, A., Saudek, F., Witkowski, P., Golab, K., Bertuzzi, F., Gustafsson, B., Daffonchio, L., Ruffini, P.A., Piemonti, L.. - In: DIABETES CARE. - ISSN 0149-5992. - 43:4(2020), pp. 710-718. [10.2337/dc19-1480]
Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes
Maffi, PaolaPrimo
;Piemonti, Lorenzo
Ultimo
2020-01-01
Abstract
Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allo-transplant recipients.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Targeting CXCR1 2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Tutti i diritti riservati
Dimensione
1.17 MB
Formato
Adobe PDF
|
1.17 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
